medRxiv PreprintsInternational20 November 2026
Amyotrophic lateral sclerosis progression is tracked in plasma by systemic proteins independent of motor neurons
This is an official announcement record
Firsthand records what medRxiv Preprints announced and links to the original. The wording below is theirs, not ours.
Blood biomarkers that change as patients with amyotrophic lateral sclerosis (ALS) decline would allow progression to be monitored more objectively. Plasma proteomic studies have identified proteins that differ between patients and controls, but which plasma proteins change as patients decline, and whether they come from motor neurons, is unknown. Here, we leveraged the Answer ALS cohort, with serial SomaScan plasma proteomics, repeated ALS Functional Rating Scale-Revised assessments, and induced pluripotent stem cell-derived motor neurons (iMNs) from the same patients. At baseline, 77 plasma p
Read the official announcement
Opens www.medrxiv.org
More from medRxiv Preprints
- Unmet needs of Polish patients with cystic fibrosis seen through the lens of crowdfunding20 November 2026
- Motherly Plus: Study Protocol of a Randomized Controlled Trial Evaluating a Smartphone-Assisted Single-Session Psychotherapy Intervention for Postpartum Depression20 November 2026
- Targeting memory consolidation in major depression via pharmacological slow-wave sleep promotion20 November 2026
- Epidemiology of Cardiac Structure and Function Among African Caribbeans in Tobago: A Population-based Cohort Study20 November 2026
- Depressive Symptom Trajectories and Incident Cognitive Impairment by Outcome Ascertainment20 November 2026
This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.